Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
MOHCCN-O
1 other identifier
observational
500
1 country
3
Brief Summary
The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2022
Longer than P75 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 30, 2022
CompletedFirst Posted
Study publicly available on registry
June 3, 2022
CompletedStudy Start
First participant enrolled
June 23, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 1, 2026
February 3, 2025
January 1, 2025
4.3 years
May 30, 2022
January 29, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data
Consolidate and annotate data from patients included in a pan-Canadian cohort
5 years
Secondary Outcomes (3)
Development of standard practices to create a unique shareable dataset of molecular, imaging, clinical and health outcome information on Canadian cancer cases
5 years
Clinical effectiveness and cost-effectiveness of precision cancer medicine to advance clinical implementation and reimbursement decisions
5 years
Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine
5 years
Study Arms (1)
MOHCCN-O
Tumor tissue and blood samples will be collected from patients who are enrolled in this study but do not yet have the molecular profiling data that are required to meet the gold standard criteria. Data will include: pathology, clinical biomarkers, imaging diagnostic information, whole genome and epi-genome sequencing of tumor and normal tissues, immunoprofiling of tumor tissues and/or peripheral blood, bioinformatic annotation of molecular information, and longitudinal clinical and outcome data.
Eligibility Criteria
Any cancer patient
You may qualify if:
- Patients with histological and/or cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy
- All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:
- Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1)
- Have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization
- Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling.
- Participating patients must agree to share their anonymized clinical and genomic data
You may not qualify if:
- None.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University Health Network, Torontolead
- Princess Margaret Hospital, Canadacollaborator
- Ontario Institute for Cancer Researchcollaborator
- Terry Fox Research Institutecollaborator
- Queen's University, Kingston, Ontariocollaborator
- Ottawa Hospital Research Institutecollaborator
- Queen's Universitycollaborator
Study Sites (3)
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7, Canada
Ottawa Health Research Institute
Ottawa, Ontario, K1Y 4E9, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, M5G2M9, Canada
Biospecimen
Tumour tissues and blood samples will be collected from patients who are enrolled. Biopsy - up to 6 cores of tumour samples (1 time only) Blood - 20 mL collected in 2 x 10mL tubes (1 time only) Requesting archival: 10 x 10 um plus 1 H\&E of Formalin-fixed paraffin embedded
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lillian Siu, MD
University Health Network, Toronto
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 30, 2022
First Posted
June 3, 2022
Study Start
June 23, 2022
Primary Completion (Estimated)
October 1, 2026
Study Completion (Estimated)
October 1, 2026
Last Updated
February 3, 2025
Record last verified: 2025-01